CRISPR effectors, which comprise a CRISPR-Cas protein and a guide (g)RNA derived from the bacterial immune system, are widely used to induce double-strand breaks in target DNA and activate the in-vivo DNA repair system for target-specific genome editing. When the gRNA recognizes genomic loci with sequences that are similar to the target, deleterious and often carcinogenic mutations can occur. Offtarget mutations with a frequency below 0.5% remain mostly undetected by current genome-wide off-target detection techniques. In this study, we developed a method to effectively detect extremely small amounts of mutated DNA based on predicted off-target-specific amplification. We used various genome editors, including CRISPRCpf1, Cas9, and an adenine base editor, to induce intracellular genome mutations.
Introduction
The CRISPR-Cas system, consisting of various Cas proteins and guide (g) RNA, is a bacterial or archaea immune system required to defend viral DNA through target sequence specific cleavage. The CRISPR-Cas system allows targeted editing of genes of interest in various organisms, from bacteria to humans, and has versatile applications in vivo 1, 2 . However, when the CRISPR system recognizes sequences similar to the target sequence, deleterious off-target mutations can occur, especially in mammals given their large genomes, which can lead to malfunctions 3 . Offtargeting issues due to guide (g)RNA characteristics have been reported for various CRISPR effectors, such as Cas9 and Cas12 (Cpf1) [4] [5] [6] [7] [8] . Consistently, there is a need for precise control of CRISPR-Cas function, and in particular, for a method to develop CRISPR effectors [9] [10] [11] that precisely target a desired locus while avoiding offtarget effects, before CRISPR effectors can be introduced for human therapeutic purposes 12 .
To date, various methods, mostly based on next-generation sequencing (NGS), have been developed to detect the off-target mutations in vivo 13 . These methods detect genome-wide off-target mutations in an unbiased fashion both inside and outside the cell. However, the current methods often result in ambiguous or no detection of offtarget mutations, particularly, when they are below the sequencing error rate (<0.5%).
In addition, these methods detect non-common variations other than shared offtarget mutations, and thus require additional validation. In order to measure a small amount of off-target mutations caused by the above effectors with high sensitivity, a method to enrich and relatively amplify the mutated over the much more abundant wild-type DNA using CRISPR endonucleases based on previous method(CRISPRmediated, ultrasensitive detection of target DNA (CUT)-PCR) was developed 14 . First, all off-target candidate sequences similar to the given CRISPR effector target sequence are selected by in-silico prediction. Subsequently, wild-type DNA that does not have mutations in each of the off-target candidate sites is eliminated by the effector to enrich mutant DNA, which is then PCR-amplified, thus enabling the detection of extremely small amounts of mutant DNA with a sensitivity superior to that of conventional deep sequencing methods. CRISPR amplification based off-target mutation enrichment was never tried with genomic DNA before and we further enhanced this method with direct amplification on cell extracted genomic DNA.
With the rapid advancements in CRISPR-Cas genome editing technologies, their application in human gene therapy is being considered 1, 15 . Therefore, there is an urgent need for a method to accurately detect whether or not CRISPR effectors operate at unwanted off-target sites. This study aimed to develop a method for detecting very small amounts of off-target mutations (below the detection limit of deep sequencing) derived from genetic modification of specific sequences using CRISPR amplification technology in vivo with high accuracy.
Results

Effective mutant DNA fragment enrichment with CRISPR amplification
The existing NGS methods have limited sensitivity in detecting genome-wide offtarget mutations induced by CRISPR effectors in vivo. To overcome this limitation, we developed a method for amplifying and analyzing a small amount of mutations on CRISPR effector treated genomic DNA. To detect the off-target mutations, we designed a CRISPR amplification method to allow relative amplification of a small amount of mutant DNA fragments over wild-type DNA. The principle of this method is shown in (Fig. 1a) . First, the off-target sequences similar to the target sequence are predicted in silico. Then, genomic DNA is extracted from CRISPR-edited cells, and on-target and predicted off-target genome sequences are PCR-amplified.
Subsequently, the amplicons are processed by the CRISPR effector (using the same or optimally designed gRNA to remove wild-type DNA other than mutant DNA), and the enriched mutant DNA fragments are PCR-amplified. Amplicons obtained by 3 times repeated CRISPR effector cutting and PCR amplification are then barcoded by nested PCR and subjected to NGS. The indel frequency (%) is calculated to evaluate the presence of off-target mutations. To verify that mutated DNA was indeed relatively amplified over non-mutated DNA by this method, we edited HEK293FT cells using the CRISPR-Cpf1 system to induce indels in target sequences and applied the CRISPR amplification method to genomic DNA samples extracted from the cells (Fig. 1b-d) . As shown in (Fig. 1b) , targeted amplicon sequencing and genotyping( Supplementary Fig. 1a ) enabled the detection of extremely low concentrations of mutant DNA fragments (~1/100,000%) through multiple rounds of amplification by wild-type DNA specific cleavage (Fig. 1c, Top) . Only one cycle of CRISPR amplification was used to detect mutant genes with the rate around 0.01%, and three repeated assays allowed determining the indel mutation rate as low as 0.00001% (Fig. 1c, Bottom) . When analyzing the pattern of mutations that were relatively amplified by CRISPR amplification up to three times for each diluted sample from original CRISPR effector treated genomic DNA, deletion patterns were observed mainly in the CRISPR-Cpf1 target sequence, in line with previous reports 16, 17 ( Fig. 1d) . When the wild-type DNA was removed by the CRISPR effector, DNA fragments containing deletion-type mutations (Fig. 1d , Right) of various sizes were effectively amplified over non-mutated DNA fragments. The deletion pattern for the CRISPR-Cpf1 effector revealed that DNA fragments with large deletions tended to be more effectively amplified than fragments with smaller deletions (Fig. 1d, Left) .
The results indicated that a 1-bp alteration from the original sequence within the protospacer region leads to a high probability of re-cleavage by the CRISPR effector, and mutated DNA with larger indels is relatively better amplified.
Off-target property of CRISPR-Cpf1 effector is addressed by CRISPR amplification
The Cpf1 effector targets thymine-rich regions in genes. Previous studies showed that CRISPR-Cpf1 induces less off-target mutations than CRISPR-Cas9 because it is less tolerant for mismatches 6, 7 . However, off-target mutations with rates below the NGS sensitivity limit (<0.5%) may occur, which can potentially cause serious problems, particularly in therapeutic settings. To address the safety issue, we assessed whether CRISPR amplification allows the detection of a small amount of Cpf1 induced off-target mutations with high sensitivity (Fig. 2) . A targeted sequence (RPL32P3 site) in U2OS (Fig. 2a, Supplementary Fig. 1b ) and HEK293FT cells Fig. 2 ) was analyzed for Cpf1-induced mutations measured as indel frequencies (0.1%~11.2%) in off-target candidate loci predicted by in-silico Table 2 ). Ten predicted off-target sequences were processed using a optimally designed Cpf1-crRNA complex (ideally designed to Table 2 ) in U2OS cell was 7.7% (Fig. 2a) . After three rounds of CRISPR amplification, the mutant DNA fragment was amplified with an efficiency close to 100%(12.8 fold enriched). In a negative control treatment without Cpf1, the indel frequency could not be determined (~0%) by three CRISPR amplifications.
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When off-target mutation detection by CRISPR amplification was compared with the conventional targeted amplicon sequencing 19 (Fig. 2b, Supplementary Table 4 ). In particular, CRISPR amplification was able to accurately identify off-target mutations (off-target loci 4(HEK293FT) and 5(U2OS)) that were difficult to identify by conventional targeted amplicon sequencing due to the low copy number of mutant DNA. The Cpf1-induced indel pattern revealed that off-target mutations were mainly deletions rather than insertions ( Supplementary Fig.4 ). In particular, amplification of insertions was not observed above 3 rd -order enrichment. Overall, DNA fragments with large deletions around the cleavage site tended to be more effectively amplified than DNAs with smaller deletions. For CRISPR-Cpf1 off-target analysis at several loci, mutations were introduced in the DNMT1 gene in HEK293FT cells (Fig. 3a, Supplementary   Fig. 7b ). In addition to the indel frequency at the target sequence, the indel frequencies at two out of the three off-target genes predicted in silico (Table 2) were determined ( Fig. 3a, Supplementary Fig. 1c ). In particular, indel mutations in offtarget locus 2 that were difficult to detect by targeted amplicon sequencing were identified by CRISPR amplification (Fig. 3a , b, Supplementary Table 5) , and in offtarget locus 1, no significant mutation was detected by this method. The indel pattern for each locus analyzed by sequencing revealed that deletions rather than insertions were the major enriched mutations in target and off-target sequences in the DNMT1-site3 locus ( Supplementary Fig. 5a ).
Off-target detection for the CRISPR-Cas9 effector by CRISPR amplification
To verify the potential of the Cas9 effector for inducing off-target mutations at the cellular level, CRISPR amplification was applied to detect candidate off-target mutations (Supplementary Table 2 ) predicted based on the target sequence in HEK293FT edited with CRISPR-Cas9 (Fig. 3c) . In order to selectively amplify the mutated over wild-type DNA, the seed region of CRISPR-Cas9 target sequence was designed to harbor the PAM sequence (TTTN) of Cpf1 used for wild-type DNA cleavage ( Supplementary Fig. 7c ). CRISPR amplification revealed a significant increase in indels in the target DNA, which was confirmed by NGS ( Table 2) , and unique indel patterns were detected at off-target site 3 (Fig. 3c, d, Supplementary Fig. 6b ). Conventional NGS did not allow detection of the off-target indels with frequencies below the detection limit. However, when the amplicon was subjected to third rounds of CRISPR amplification, even 1-bp-deletions were detected at a significant rate (51-fold increase vs. without amplification) (Fig. 3d, Supplementary Fig. 6b , Supplementary Table 6 ).
Single-base substituted off-target detection for adenine base editor (ABE) by
CRISPR amplification
In addition to the insertions/deletions caused by target DNA cleavage by the CRISPR effector, we evaluated whether the CRISPR amplification can be used to detect single-base changes caused by off-target effects of adenine base editor (ABE) (Fig.   4 ). To this end, first, ABE and gRNA (Supplementary Table 1 ) expression vectors were transfected into HEK293FT cells to induce single base substitutions at target genomic loci. Next, the genomic DNA extracted from the cells was subjected to CRISPR amplification for candidate off-target sequences predicted based on the gRNA sequence for the target DNA (PSMB2) (Fig. 4a) . To specifically amplify basechanged over wild-type DNA, the PAM sequence (TTTN) recognized by Cpf1 was placed in a window where the base substitution is mainly generated in the target sequence ( Supplementary Fig. 7d ). If the PAM sequence recognized by Cpf1 has a base substitution, wild-type DNA without base substitution can be removed. Three cycles of CRISPR amplification on samples treated with ABE (PSMB2 site) Table 2 ) revealed that DNA fragments with a base substitution (A>G) in the ABE editing window were significantly amplified (75.6% substitution, 7.67 fold increase) (Fig. 4b) . The base substitution (A>G) was found to occur mainly at adenine sites in the 12-18-bp window within the ABE target sequence (Fig. 4c) .
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The amount of the base substitution gradually increased with increasing cycles of CRISPR amplification. Next, CRISPR amplification was applied to predicted offtarget sites (Supplementary Table 2 ). The A>G base substitution was significantly induced in each of the off-target sequences (off-targets 2, 3, and 4 in Fig. 4a, c) . A low amount of base substitution could not be detected by NGS, but it was detected by CRISPR amplification (434, 272.5 and 58 fold increase respectively) (Fig. 4b, Supplementary Table 7) . Interestingly, in contrast to target sequences, where the A>G base substitution occurred evenly within the window of the guide sequence (12-18 bp), intensive base substitutions occurred at the 18th adenine from the PAM sequence in off-target sequences as indicated by CRISPR amplification (Fig. 4c) .
Discussion
As the CRISPR system is based on gRNAs that bind complementarily to target genes, it often causes mutations at unintended genomic loci with similar sequences.
Efforts have been made to identify the presence of the off-target mutations, and to prevent their formation. In order to overcome the limitations regarding the sensitivity of current methods based on genome-wide analysis, we developed a method to amplify and detect small amounts of off-target mutations in intracellular genes generated by CRISPR effectors. The key of the mutated gene amplification method using CRISPR, developed in this study, is to enrich mutant genes containing offtarget sequences predicted in silico and to remove the background wild-type DNA before PCR amplification.
As the CRISPR effectors, currently in use, sensitively recognize PAM sequences in the target DNA and the seed sequence of the protospacer, we considered these sequences when designing the gRNA. In particular, in the case of base editors that induce single-nucleotide substitutions, fragments containing mutations can be efficiently amplified by constructing a gRNA such that the PAM sequence is disrupted when a mutation is introduced. Our detection method using CRISPR amplification has various advantages. First, a very small amount of mutant DNA can be enriched in one round of CRISPR amplification, and stepwise amplification shows high sensitivity in detecting mutant DNA fragments of up to (0.00001%). Second, mutant genes can be easily amplified in a high-throughput manner. Third, as a gRNA and CRISPR effector are used, the method can be widely applied to insertions/deletions and single base substitutions generated by various CRISPR effectors. In addition, it is possible to apply the method to precisely analyze whether mutations are induced in off-target sequences by using new techniques, such as prime editing. One prerequisite of the current CRISPR amplification method is the need for accurate insilico prediction of potential off-target sites, for which several online tools are available. Another technical difficulty is that there is a possibility of error incorporation during sequential PCR amplifications. In order to overcome this problem, Phusion
High-Fidelity DNA Polymerase 20 with an extremely low error rate was used, and a maximum of three amplification cycles was used based on a negative control experiment which does not shows significant enrichment of mutation patterns (Fig.   2a, Fig. 3a,c, Fig. 4a ).
Using the method developed in this study, we analyzed the off-target mutation propensity of CRISPR-Cpf1, CRISPR-Cas9, and ABE. The Cpf1 and Cas9 effectors respectively recognize T-and G-rich PAM sequences and bind to the sequences complementary to the gRNA in the target DNA to induce double-helix cleavage.
These effectors are known to be very sensitive to mismatches in the PAM proximal region and less sensitive to mismatches in PAM distal regions. In this study, we compared CRISPR amplification with conventional NGS (next generation sequencing) or previously reported GUIDE-seq data for the detection of off-target mutations induced by CRISPR-Cpf1. Both methods revealed five off-target mutations for RPL32P3 site in U2OS or HEK293FT cell, including various mutations in the PAM distal region. Our method allowed the amplification and detection of mutations present at levels below the NGS detection level. In addition, three off-target mutations in DNMT1 were tested by our method. In particular, off-target indels with a very low read number in conventional NGS were effectively amplified by our CRISPR amplification method. Similar to the findings for CRISPR-Cpf1, when intracellular target mutation was induced by CRISPR-Cas9, mutations below the NGS detection level were detected at a high significance level in one of the in-silico predicted offtarget loci. Surprisingly, in addition to the insertion/deletions caused by double-helix cleavage by CRISPR-Cpf1 or -Cas9, single-base substitutions at off-target sites induced by ABE were detected at very high significance levels. Using adequately designed gRNAs and CRISPR amplification, extremely small amounts of off-target base substitution (A>G) below the NGS detection level could be detected, and the sensitivity was augmented with increasing CRISPR amplification cycles.
The highly sensitive off-target mutation discovery method developed in this study can be combined with genome-wide methods for highly probable off-target candidate selection. After detecting the off-target candidates, CRISPR amplification can be applied to determine the authenticity of off-target candidates and to finally determine whether a specific gRNA can be used for gene therapy. In addition, it is possible to accurately analyze the tendency of existing gene editors to induce mutations that cannot be detected by NGS technologies and intracellular mutation patterns generated by newly developed gene editors. Finally, the CRISPR amplification technology can be applied to remove background wild-type DNA and enrich DNA mutations induced by newly developed gene editors, including prime editing, which will contribute to ultra-precision genome correction.
Methods
Protein purification 1 mM DTT, 40% glycerol) using Centricon filters (Amicon Ultra) and the samples were aliquoted and stored at -80°C. Purity of the purified protein was confirmed by SDS-PAGE (10%), and protein activity was confirmed by an in-vitro PCR amplicon cleavage assay.
In-vitro gRNA synthesis
For in-vitro transcription, DNA oligos containing a crRNA sequence (Supplementary with DNase at 37°C for 1 h, and the RNA was purified using a GENECLEAN ® Turbo
Kit (MP Biomedicals). The purified RNA was concentrated through lyophilization (2,000 rpm, 1 h, -55°C, 25°C).
Cell culture and transfection
HEK293FT and U2OS human cells were obtained from the American Type Culture Transfected cells were transferred to a 24-well plate containing DMEM (500 l/well),
pre-incubated at 37°C in the presence of 5% CO 2 for 30 min, and incubated under the same conditions for subculture. After 48 h, genomic DNA was isolated using a DNeasy Blood & Tissue Kit (Qiagen).
Genotyping by in-vitro cleavage
PCR amplicons were obtained from genomic DNA (from HEK293FT or U2OS) using DNA primers (Supplementary Table 3 ) corresponding to each target and non-target candidate gene locus. Purified recombinant Cpf1 and crRNA designed to remove DNA other than intracellularly induced mutant DNA were purified and premixed, and incubated in cleavage buffer (NEB3, 10 l) at 37°C for 1 h. The reaction was stopped by adding a stop buffer (100 mM EDTA, 1.2% SDS), and DNA cleavage was confirmed by 2% agarose gel electrophoresis. DNA cleavage efficiency was calculated based on the cleaved band image pattern according to the formula:
intensity of the cleaved fragment/total sum of the fragment intensity  100%, using
ImageJ software.
Enrichment and validation of CRISPR-Cpf1 off-target mutations
A crRNA corresponding to the nucleotide sequence within the target gene was prepared (Supplementary Table 1) , and cells were transfected with plasmids expressing CRISPR-Cpf1 and the crRNA to induce genome mutation at the desired site. The target site (RPL32P3 site in human genomic DNA (Supplementary Table   2 )) was selected considering the editing efficiency of Cpf1 at the given genome location. Cas-OFFinder 18 was used to identify genome-wide candidate off-target sites derived from the target sequence (Supplementary Table 2 Table 3) ).
Enrichment and validation of CRISPR-Cas9 off-target mutations
To use CRISPR-Cas9 to induce mutations, a gRNA was designed and a gRNA expression plasmid was transfected into cells. The target was selected based on a high editing efficiency of the CRISPR-Cas9 effector (FAT3 site in human genomic Table 3) ). CRISPR amplification was performed using a crRNA (Table) designed to remove DNA other than mutant DNA. Subsequent steps were the same as described for CRISPR-Cpf1
off-target mutation analysis.
Enrichment and validation of ABE off-target mutations
To use CRISPR-Cas9-based ABE to induce mutations, a gRNA complementary to the target sequence was prepared (Supplementary Table 1 Fig. 7d , Supplementary Table1) to remove DNA other than mutant DNA. Subsequent steps were the same as described for CRISPR-Cpf1 off-target mutation analysis.
Targeted deep sequencing and data analysis
To confirm whether mutations were introduced in the target genome locus by the CRISPR-Cpf1, CRISPR-Cas9 or adenine base editor, genomic DNA extracted from cells was amplified using DNA primers (Supplementary Table 3 
